文献速递免疫规划妇幼与学校卫生

九价与二价HPV疫苗混合接种36个月免疫原性随访

Follow up immunogenicity of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccines 36 months post-vaccination among boys and girls.
PubMed 文献 · Vaccine · 2026-09-03

在9–10岁儿童中比较两剂九价HPV同源接种与九价/二价混合接种方案,36个月时HPV16/18抗体在所有337名参与者中均100%可检出;混合方案对其他型别抗体可检出率为94–100%,且HPV16/18的GMC显著高于同源九价方案,支持混合两剂方案的可行性。

要点

  • 混合接种36个月后HPV16/18抗体100%可检出。
  • 混合方案HPV16/18的GMC显著高于两剂九价同源方案。
  • 混合方案对其他型别抗体可检出率94–100%。

核心结论

  • 混合HPV疫苗接种方案的血清学应答至少持续36个月,对HPV16/18与两剂九价方案相当。

研究设计与样本

  • 9–10岁女童和男童按1:1随机分配,接受两剂九价HPV(n=168,ATP)或混合方案(n=169,ATP),混合方案为2vHPV+9vHPV(n=86)或9vHPV+2vHPV(n=83),间隔6个月。

主要发现

  • 36个月时所有337名参与者HPV16和HPV18抗体均100%可检出。
  • 混合方案对其他九价靶型抗体可检出率为94–100%,两剂九价方案为100%。
  • HPV16的GMC:混合方案9vHPV+2vHPV为184.6(145.5-234.3)、2vHPV+9vHPV为151.7(121.2-189.8),均高于同源九价方案的97.7(83.6-114.1)。
  • HPV18的GMC:混合方案9vHPV+2vHPV为70.4(53.5-92.7)、2vHPV+9vHPV为72.7(57.0-92.8),均高于同源九价方案的40.3(34.9-46.6)。
  • 9vHPV+2vHPV混合方案的GMC高于2vHPV+9vHPV方案;性别分层分析未见男女间实质性差异。

临床怎么用

  • 混合两剂HPV接种方案在36个月时对HPV16/18的免疫应答与两剂九价方案相当,可作为可行性证据参考。

局限性

  • 需进一步研究临床效果和实施情况以支持政策决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Following up on previously published short-term findings, we assessed the persistence of the immune response at 36 months following mixed-HPV vaccination schedules using one nonavalent (9vHPV) dose and one bivalent (2vHPV) dose (administered interchangeably) compared to a homologous two-dose 9vHPV schedule. METHODS: Girls and boys aged 9-10 years were randomized (1:1) to receive (I) two doses of 9vHPV (n = 168 according-to-protocol (ATP)) or (II) a mixed schedule (n = 169 ATP) of 2vHPV + 9vHPV (n = 86) or 9vHPV + 2vHPV (n = 83) with a 6-month interval. The proportion of participants with detectable antibodies and geometric mean concentrations (GMCs) for HPV types 6/11/16/18/31/33/45/52/58 were measured using M9ELISA at 7 and 36 months after the first dose. RESULTS: Antibodies to HPV16 and HPV18 persisted in all 337 participants (100%) at 36 months. Antibodies to the other 9vHPV-targeted types were detectable in 94-100% of participants vaccinated with a mixed schedule versus 100% for those vaccinated with a 2-dose 9vHPV schedule. GMCs for HPV16 and HPV18 were significantly higher in those vaccinated with a mixed schedule (9vHPV + 2vHPV and 2vHPV + 9vHPV) compared to the 9vHPV + 9vHPV schedule: 184.6 (145.5-234.3) and 151.7 (121.2-189.8) vs 97.7 (83.6-114.1) for HPV16, and 70.4 (53.5-92.7) and 72.7 (57.0-92.8) vs 40.3 (34.9-46.6) for HPV18. Additionally, the 9vHPV + 2vHPV mixed schedule resulted in higher GMCs when compared to the 2vHPV + 9vHPV schedule. GMC ratios (homologous/mixed schedules) decreased for HPV types not included in the bivalent vaccine, indicating that differences observed at 7 months were reduced at 36 months. Sex-stratified analyses showed no substantial differences between boys and girls. CONCLUSION: Serological responses of mixed-HPV vaccination schedules are sustained for at least 36 months post-vaccination and comparable to a 2-dose 9vHPV schedule, for HPV16/18. These findings provide immunogenicity evidence supporting the feasibility of mixed 2-dose HPV schedules, while further research on clinical effectiveness and implementation is needed to inform policy decisions. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov (NCT02567955).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ionescu IG, Ouakki M, Breton O, et al. Follow up immunogenicity of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccines 36 months post-vaccination among boys and girls. Vaccine. 2026. PMID: 42691819. doi:10.1016/j.vaccine.2026.129107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。